Elevated serum level of IL-4 in neuromyelitis optica and multiple sclerosis patients

References

• Jarius, S.; Wildemann, B.; Paul, F. Neuromyelitis Optica: Clinical Features, Immunopathogenesis and Treatment. Clin. Exp. Immunol. 2014, 176(2), 149–164. DOI: 10.1111/cei.12271.
   PubMed Web of Science ®Google Scholar
• Etemadifar, M.; Jahanbani-Ardakani, H.; Ghaffari, S.; Fereidan-Esfahani, M.; Changaei, H.; Aghadoost, N.; Ardakani A. J; Moradkhani N. Cancer Risk among Patients with Multiple Sclerosis: A Cohort Study in Isfahan, Iran. Caspian J. Intern. Med. 2017, 8(3), 172.
   PubMed Web of Science ®Google Scholar
• Loma, I.; Heyman, R. Multiple Sclerosis: Pathogenesis and Treatment. Curr. Neuropharmacol. 2011, 9(3), 409–416. DOI: 10.2174/157015911796557911.
   PubMed Web of Science ®Google Scholar
• Farrokhi, M.; Masoudifar, A.; Derakhshan, A.; Saadatmand, S.; Rouhi-Boroujeni, H.; Etemadifar, M.;. et al. The Association of Interleukin-16 Gene Polymorphisms with IL-16 Serum Levels and Risk of Multiple Sclerosis. Immunol. Invest. 2017, 1–9. DOI:10.1080/08820139.2016.1268154.
   PubMedGoogle Scholar
• Alsahebfosoul, F.; Salehi, R.; Kazemi, M.; Ghaffari, S.; Jahanbani-Ardakani, H.; Etemadifar, M.; Abtahi S. H. CD25 Gene Polymorphism and Multiple Sclerosis; Elsevier,2017.
   Google Scholar
• Mealy, M. A.; Wingerchuk, D. M.; Greenberg, B. M.; Levy, M. Epidemiology of Neuromyelitis Optica in the United States: a Multicenter Analysis. Archiv. Neurol. 2012, 69(9), 1176–1180. DOI: 10.1001/archneurol.2012.314.
   PubMedGoogle Scholar
• Etemadifar, M.; Izadi, S.; Nikseresht, A.; Sharifian, M.; Sahraian, M. A.; Nasr, Z. Estimated Prevalence and Incidence of Multiple Sclerosis in Iran. Eur. Neurol. 2014, 72(5–6), 370–374. DOI: 10.1159/000365846.
   PubMed Web of Science ®Google Scholar
• Kashipazha, D.; Mohammadianinejad, S. E.; Majdinasab, N.; Azizi, M.; Jafari, M. A Descriptive Study of Prevalence, Clinical Features and Other Findings of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Khuzestan Province, Iran. Iran. J. Neurol. 2015, 14(4), 204–210.
   PubMed Web of Science ®Google Scholar
• Etemadifar, M.; Dashti, M.; Vosoughi, R.; Abtahi, S. H.; Ramagopalan, S. V.; Nasr, Z. An Epidemiological Study of Neuromyelitis Optica in Isfahan. Mult. Scler. 2014, 20(14), 1920–1922. DOI: 10.1177/1352458514537699.
   PubMed Web of Science ®Google Scholar
• Dabiri, A.; Mansouri, R.; Kazemi, M.; Eskandari, N.; Shaygannejad, V.; Manian, M.; Jahanbani-Ardakani H. OX40 Gene Expression and Its Serum Levels in New Cases of Patients with Multiple Sclerosis. Adv. Neuroimmune Biol. 2018, 7(1), 49–52.
   Web of Science ®Google Scholar
• Farokhi, M.; Etemadifar, M.; Rezaei, A.; Amani, A.; Jahanbani, H. Role of Histamine and Diamine Oxidase Enzyme in Multiple Sclerosis. Mult. Scler. Relat. Disord. 2014, 3(6), 746. DOI: 10.1016/j.msard.2014.09.170.
   Google Scholar
• Jahanbani-Ardakani, H.; Alsahebfosoul, F.; Moshfeghi, S.-R.; Mahaki, B.; Etemadifar, M.; Abtahi, S.-H.; Fereidan-Esfahani M. Serum Level of Interleukin 12 in Patients with Multiple Sclerosis. Int. J. Neurosci. 2018, (just-accepted) 1–7.
   Web of Science ®Google Scholar
• Kouchaki, E.; Tamtaji, O. R.; Dadgostar, E.; Karami, M.; Nikoueinejad, H.; Akbari, H. Correlation of Serum Levels of IL-33, IL-37, Soluble Form of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), and Circulatory Frequency of VEGFR2-expressing Cells with Multiple Sclerosis Severity. Iran. J. Allergy Asthma Immunol. 2017, 16(4), 329–337.
   PubMed Web of Science ®Google Scholar
• Wei, Y.; Chang, H.; Feng, H.; Li, X.; Zhang, X.; Yin, L. Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes. Front. Neurol. 2019, 10, 604. DOI: 10.3389/fneur.2019.00604.
   PubMed Web of Science ®Google Scholar
• Powers, R.; Garrett, D. S.; March, C. J.; Frieden, E. A.; Gronenborn, A. M.; Clore, G. M. Three-dimensional Solution Structure of Human Interleukin-4 by Multidimensional Heteronuclear Magnetic Resonance Spectroscopy. Faculty Publications–Chemistry Department. 1992, 4.
   Google Scholar
• Derecki, N. C.; Cardani, A. N.; Yang, C. H.; Quinnies, K. M.; Crihfield, A.; Lynch, K. R.; Kipnis J. Regulation of Learning and Memory by Meningeal Immunity: a Key Role for IL-4. J. Exp. Med. 2010, 207(5), 1067–1080.
   PubMed Web of Science ®Google Scholar
• Howard, M.; Farrar, J.; Hilfiker, M.; Johnson, B.; Takatsu, K.; Hamaoka, T.; Paul W. E. Identification of a T Cell-derived B Cell Growth Factor Distinct from Interleukin 2. J. Exp. Med. 1982, 155(3), 914–923.
   PubMed Web of Science ®Google Scholar
• Hu-Li, J.; Shevach, E.; Mizuguchi, J.; Ohara, J.; Mosmann, T.; Paul, W. B Cell Stimulatory Factor 1 (interleukin 4) Is a Potent Costimulant for Normal Resting T Lymphocytes. J. Exp. Med. 1987, 165(1), 157–172. DOI: 10.1084/jem.165.1.157.
   PubMed Web of Science ®Google Scholar
• Nelms, K.; Keegan, A. D.; Zamorano, J.; Ryan, J. J.; Paul, W. E. The IL-4 Receptor: Signaling Mechanisms and Biologic Functions. Annu. Rev. Immunol. 1999, 17(1), 701–738. DOI: 10.1146/annurev.immunol.17.1.701.
   PubMed Web of Science ®Google Scholar
• Alves-Leon, S. V.; Pimentel, M. L.; Sant’Anna, G.; Malfetano, F. R.; Estrada, C. D.; Quirico-Santos, T. Immune System Markers of Neuroinflammation in Patients with Clinical Diagnose of Neuromyelitis Optica. Arq. Neuro-psiquiatr. 2008, 66(3b), 678–684.
   PubMed Web of Science ®Google Scholar
• Bartosik-Psujek, H.; Stelmasiak, Z. Correlations between IL-4, IL-12 Levels and CCL2, CCL5 Levels in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. J. neural trans. 2005, 112(6), 797–803. DOI: 10.1007/s00702-004-0225-9.
   PubMed Web of Science ®Google Scholar
• Chang, K. H.; Ro, L. S.; Lyu, R. K.; Chen, C. M. Biomarkers for Neuromyelitis Optica. Int. J. Clin. Chem. 2015, 440, 64–71. DOI: 10.1016/j.cca.2014.11.004.
   Google Scholar
• Hohnoki, K.; Inoue, A.; Koh, C. S. Elevated Serum Levels of IFN-gamma, IL-4 and TNF-alpha/unelevated Serum Levels of IL-10 in Patients with Demyelinating Diseases during the Acute Stage. J. Neuroimmunol. 1998, 87(1–2), 27–32.
   PubMed Web of Science ®Google Scholar
• Wang, K. C.; Lee, C. L.; Chen, S. Y.; Chen, J. C.; Yang, C. W.; Chen, S. J.; Tsai C. P. Distinct Serum Cytokine Profiles in Neuromyelitis Optica and Multiple Sclerosis. J. Interferon Cytokine Res. 2013, 33(2), 58–64.
   PubMed Web of Science ®Google Scholar
• Tan, C. T.; Mao, Z.; Qiu, W.; Hu, X.; Wingerchuk, D. M.; Weinshenker, B. G. International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders. Neurology. 2016, 86(5), 491–492. DOI: 10.1212/WNL.0000000000002366.
   PubMed Web of Science ®Google Scholar
• Polman, C. H.; Reingold, S. C.; Banwell, B.; Clanet, M.; Cohen, J. A.; Filippi, M.; et al. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Ann. Neurol. 2011, 69(2), 292–302.
   PubMed Web of Science ®Google Scholar
• Ponomarev, E. D.; Maresz, K.; Tan, Y.; Dittel, B. N. CNS-derived Interleukin-4 Is Essential for the Regulation of Autoimmune Inflammation and Induces a State of Alternative Activation in Microglial Cells. J. Neurosci. 2007, 27(40), 10714–10721. DOI: 10.1523/JNEUROSCI.1922-07.2007.
   PubMed Web of Science ®Google Scholar
• Ziv, Y.; Ron, N.; Butovsky, O.; Landa, G.; Sudai, E.; Greenberg, N.; Cohen H; Kinis J; Schwartz M. Immune Cells Contribute to the Maintenance of Neurogenesis and Spatial Learning Abilities in Adulthood. Nat. Neurosci. 2006, 9(2), 268–275.
   PubMed Web of Science ®Google Scholar
• Hart, P. H.; Vitti, G. F.; Burgess, D. R.; Whitty, G. A.; Piccoli, D. S.; Hamilton, J. A. Potential Antiinflammatory Effects of Interleukin 4: Suppression of Human Monocyte Tumor Necrosis Factor Alpha, Interleukin 1, and Prostaglandin E2. Proc. National Academy Sci. 1989, 86(10), 3803–380s7. DOI: 10.1073/pnas.86.10.3803.
   PubMed Web of Science ®Google Scholar
• Major, J.; Fletcher, J. E.; Hamilton, T. A. IL-4 Pretreatment Selectively Enhances Cytokine and Chemokine Production in Lipopolysaccharide-stimulated Mouse Peritoneal Macrophages. J. Immunol. 2002, 168(5), 2456–2463. DOI: 10.4049/jimmunol.168.5.2456.
   PubMed Web of Science ®Google Scholar
• Chao, C. C.; Hu, S.; Peterson, P. K. Modulation of Human Microglial Cell Superoxide Production by Cytokines. J. Leukocyte Biol. 1995, 58(1), 65–70. DOI: 10.1002/jlb.58.1.65.
   PubMed Web of Science ®Google Scholar
• Hulshof, S.; Montagne, L.; De Groot, C. J.; Van Der Valk, P. Cellular Localization and Expression Patterns of Interleukin-10, Interleukin-4, and Their Receptors in Multiple Sclerosis Lesions. Glia. 2002, 38(1), 24–35.
   PubMed Web of Science ®Google Scholar
• Shah, V. B.; Huang, Y.; Keshwara, R.; Ozment-Skelton, T.; Williams, D. L.; Keshvara, L. Beta-glucan Activates Microglia without Inducing Cytokine Production in Dectin-1-dependent Manner. J. Immunol. 2008, 180(5), 2777–2785. DOI: 10.4049/jimmunol.180.5.2777.
   PubMed Web of Science ®Google Scholar
• Furlan, R.; Bergami, A.; Lang, R.; Brambilla, E.; Franciotta, D.; Martinelli, V.; Comi G; Panina P; Martino G. Interferon-β Treatment in Multiple Sclerosis Patients Decreases the Number of Circulating T Cells Producing interferon-γ and Interleukin-4. J. Neuroimmunol. 2000, 111(1), 86–92.
   PubMed Web of Science ®Google Scholar
• Uzawa, A.; Mori, M.; Arai, K.; Sato, Y.; Hayakawa, S.; Masuda, S.; Taniguchi J; Kuwabara S. Cytokine and Chemokine Profiles in Neuromyelitis Optica: Significance of Interleukin-6. Mult. Scler. 2010, 16(12), 1443–1452.
   PubMed Web of Science ®Google Scholar
• Lucchinetti, C. F.; Mandler, R. N.; McGavern, D.; Bruck, W.; Gleich, G.; Ransohoff, R. M.; et al. A Role for Humoral Mechanisms in the Pathogenesis of Devic’s Neuromyelitis Optica. Brain. 2002, 125(7), 1450–1461.
   PubMedGoogle Scholar
• Chihara, N.; Aranami, T.; Sato, W.; Miyazaki, Y.; Miyake, S.; Okamoto, T.; Ogawa M; Toda T; Yamamura T. Interleukin 6 Signaling Promotes Anti-aquaporin 4 Autoantibody Production from Plasmablasts in Neuromyelitis Optica. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(9), 3701–3706.
   PubMed Web of Science ®Google Scholar